Quince SEC Filings

Quince Therapeutics director Christopher J. Senner received a grant of 2,700 stock options for common stock. These options have an exercise price of $0.947 per share and expire on June 11, 2036. All 2,700 options vest on the one-year anniversary of the grant date, and 2,700 derivative securities are reported as held directly after the transaction.

Quince Therapeutics, Inc. director and Chief Corp. Affairs Officer Brigette Roberts reported receiving multiple employee stock option awards for Quince common stock. On May 18, 2026, she was granted options covering several blocks of shares, including 6,837,319 options with an exercise price of $0.84 per share and additional grants such as 2,070,107 options at $0.09 per share, all classified as awards rather than market purchases or sales.

Footnotes explain these options were received in exchange for prior Orphai Therapeutics options under an Agreement and Plan of Merger involving Quince and Orphai entities. One option block begins vesting on May 21, 2026 in 36 equal monthly installments, conditioned on her continued service with the company. The filing shows only acquisitions of derivative awards, with no open-market stock trades.

Quince Therapeutics, Inc. filed an initial insider ownership report for Brigette Roberts, who is both a director and the company’s Chief Corporate Affairs Officer. The Form 3 data shows no reported purchases, sales, or other transactions in the company’s securities.

Quince Therapeutics, Inc. reported voting results from its annual stockholder meeting held online on June 11, 2026. Holders of 6,255,339 shares of common stock, representing approximately 38.37% of eligible shares, were present virtually or by proxy.

Stockholders elected Class I director June Bray to serve until the 2029 annual meeting, approved an amendment to the certificate of incorporation authorizing a reverse stock split in a range from 1-for-10 to 1-for-100 at the board’s discretion, and ratified BDO USA, P.C. as independent registered accounting firm for the fiscal year ending December 31, 2026.

Stockholders also approved, on an advisory basis, the compensation of the company’s named executive officers and approved the potential adjournment or postponement of the annual meeting to permit further proxy solicitation if necessary.

Quince Therapeutics, Inc. received a Schedule 13G disclosing that Integrated Core Strategies (US) LLC, Millennium Management LLC, Millennium Group Management LLC and Israel A. Englander report shared beneficial ownership of common stock. The filing lists individual shared holdings around 1,403,580–1,403,697 shares, representing 7.2% of the class based on 19,559,257 shares outstanding.

The filing attributes the outstanding-share base to 16,300,740 shares outstanding as of May 4, 2026 plus 3,258,517 shares issued in connection with the Orphai Therapeutics acquisition.

Quince Therapeutics, Inc. has regained compliance with Nasdaq’s continued listing standards. Nasdaq staff reviewed the company’s Form 10-Q for the quarter ended March 31, 2026, which reported stockholders’ equity of $15,672,000, and determined that Quince now meets Nasdaq Listing Rule 5450(b)(1)(A).

This closes a prior deficiency notice issued on March 17, 2026, when Quince had failed to maintain a minimum market value of listed securities of $50,000,000 over 30 consecutive business days. Nasdaq has confirmed that the compliance matter is now closed and the company remains listed on the Nasdaq Global Select Market.

Quince Therapeutics, Inc. filed an amendment to its recent report to replace the LAM-001 Phase 2a press release exhibit and correct two pulmonary vascular resistance (PVR) percentages in the efficacy table from 35.3% and 28.1% to -35.3% and -28.1%. No other changes were made.

The updated Exhibit 99.2 describes a 24-week, 10-patient, open-label Phase 2a study of inhaled LAM-001 in pulmonary arterial hypertension and PH-ILD as add-on therapy. Among six evaluable patients, six-minute walk distance improved by 81.3 meters, with a 67.4-meter gain in the PH-ILD subgroup, alongside meaningful reductions in PVR, NT-proBNP and gains in lung function.

All evaluable patients improved from Functional Class III to II by Week 24, and LAM-001 was generally well tolerated on top of standard-of-care therapies. Based on these data, Quince plans a Phase 2b PH-ILD trial starting mid-2026 and additional Phase 2 studies in BOS and SAPH.

Quince Therapeutics completed the acquisition of Orphai Therapeutics in a stock‑for‑stock merger and simultaneously arranged a large private financing to refocus the company on rare pulmonary diseases. Orphai holders received 3,258,517 Quince common shares and 67,101.235 Series C non‑voting convertible preferred shares, plus options and replacement warrants.

The company agreed to sell 144,200.633 additional Series C preferred shares and Financing Warrants to purchase 72,100.322 Series C preferred shares for about $115 million upfront and up to roughly $72 million more if the warrants are fully exercised. After the deal and Financing, Quince pre‑transaction holders would own about 6.9% of common stock, Orphai holders 31.9%, and new investors 61.2% on a fully diluted basis, while management expects cash runway through the end of 2028 to advance LAM‑001 through multiple Phase 2 milestones.

Quince Therapeutics ownership update: Nantahala Capital Management, LLC and its managing members, Wilmot B. Harkey and Daniel Mack, report beneficial ownership of 4,528,302 shares of common stock, representing 7.52% of shares outstanding as of March 31, 2026. The reported shares include 4,528,302 shares that may be acquired within sixty days through the exercise of convertible securities.